Pfizer (PFE) Receivables (2009 - 2026)

Pfizer (PFE) has reported Receivables for 18 consecutive years, with $12.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 3.41% year-over-year to $12.5 billion in Q2 2026; TTM through Jun 2026 was $12.5 billion, a 3.41% increase from a year earlier, with the FY2025 full-year figure at $11.9 billion, up 3.59% from the prior year.
• Receivables was $12.5 billion for Q2 2026 at Pfizer, down from $12.6 billion in the prior quarter.
• Over five years, Receivables peaked at $15.4 billion in Q3 2022 and troughed at $10.2 billion in Q3 2023.
• A 5-year average of $12.3 billion and a median of $12.0 billion in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables jumped 39.98% in 2022 and sank 33.68% in 2023, its largest moves.
• Over 5 years, Receivables stood at $11.0 billion in 2022, then climbed by 5.61% to $11.6 billion in 2023, then declined by 0.89% to $11.5 billion in 2024, then rose by 3.59% to $11.9 billion in 2025, then climbed by 5.19% to $12.5 billion in 2026.
• The last three Receivables figures came in at $12.5 billion (Q2 2026), $12.6 billion (Q1 2026), and $11.9 billion (Q4 2025), per Business Quant data.